DK2049557T3 - 1-(-D-glycopyranosyl)-3-(4-cyclopropylphenylmethyl)-4-halogenindolderivater og anvendelse heraf som sglt-inhibitorer - Google Patents

1-(-D-glycopyranosyl)-3-(4-cyclopropylphenylmethyl)-4-halogenindolderivater og anvendelse heraf som sglt-inhibitorer

Info

Publication number: DK2049557T3
Authority: DK; Denmark
Prior art keywords: cyclopropylphenylmethyl; haloindole; glycopyranosyl; derivatives; sglt inhibitors
Prior art date: 2006-07-27

Application number

DK07791887.8T

Other languages

English (en)

Inventor

Sumihiro Nomura

Shigeki Sakamaki

Original Assignee

Mitsubishi Tanabe Pharma Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-07-27

Filing date

2007-07-27

Publication date

2011-06-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38515468&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2049557(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-07-27 Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp

2011-06-14 Application granted granted Critical

2011-06-14 Publication of DK2049557T3 publication Critical patent/DK2049557T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Psychiatry (AREA)
Dermatology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

DK07791887.8T 2006-07-27 2007-07-27 1-(-D-glycopyranosyl)-3-(4-cyclopropylphenylmethyl)-4-halogenindolderivater og anvendelse heraf som sglt-inhibitorer DK2049557T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US82060406P	2006-07-27	2006-07-27
US88617807P	2007-01-23	2007-01-23
PCT/JP2007/065213 WO2008013322A1 (en)	2006-07-27	2007-07-27	1- (-d-glycopyranosyl) - 3 - (4-cyclopropylphenylmethyl) - 4 - halogeno indole derivatives and use thereof as sglt inhibitors.

Publications (1)

Publication Number	Publication Date
DK2049557T3 true DK2049557T3 (da)	2011-06-14

Family

ID=38515468

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK07791887.8T DK2049557T3 (da)	2006-07-27	2007-07-27	1-(-D-glycopyranosyl)-3-(4-cyclopropylphenylmethyl)-4-halogenindolderivater og anvendelse heraf som sglt-inhibitorer

Country Status (31)

Country	Link
US (1)	US7851617B2 (da)
EP (1)	EP2049557B1 (da)
JP (1)	JP5102294B2 (da)
KR (1)	KR101179312B1 (da)
CN (1)	CN101501053B (da)
AR (1)	AR062111A1 (da)
AT (1)	ATE501159T1 (da)
AU (1)	AU2007277662B2 (da)
BR (1)	BRPI0715369A2 (da)
CA (1)	CA2658116C (da)
CL (1)	CL2007002197A1 (da)
CO (1)	CO6150170A2 (da)
CR (1)	CR10583A (da)
DE (1)	DE602007013056D1 (da)
DK (1)	DK2049557T3 (da)
EA (1)	EA016819B1 (da)
GT (1)	GT200900014A (da)
HN (1)	HN2009000161A (da)
IL (1)	IL196267A0 (da)
JO (1)	JO2681B1 (da)
MX (1)	MX2009000995A (da)
MY (1)	MY145106A (da)
NO (1)	NO20085337L (da)
NZ (1)	NZ574072A (da)
PE (1)	PE20080522A1 (da)
PL (1)	PL2049557T3 (da)
PT (1)	PT2049557E (da)
TW (1)	TWI418556B (da)
UA (1)	UA92100C2 (da)
UY (1)	UY30506A1 (da)
WO (1)	WO2008013322A1 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008070609A1 (en) *	2006-12-04	2008-06-12	Janssen Pharmaceutica N.V.	Thienyl-containing glycopyranosyl derivatives as antidiabetics
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
RS56990B1 (sr)	2007-09-10	2018-05-31	Janssen Pharmaceutica Nv	Postupak za dobijanje jedinjenja koja su korisna kao inhibitori sglt
CL2008003653A1 (es) *	2008-01-17	2010-03-05	Mitsubishi Tanabe Pharma Corp	Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
WO2009117421A2 (en) *	2008-03-17	2009-09-24	Kalypsys, Inc.	Heterocyclic modulators of gpr119 for treatment of disease
BRPI0918841B8 (pt)	2008-08-28	2021-05-25	Pfizer	derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol, seus cristais, composições farmacêuticas e usos
US9056850B2 (en) *	2008-10-17	2015-06-16	Janssen Pharmaceutica N.V.	Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en) *	2009-07-08	2011-01-13	Yin Liang	Combination therapy for the treatment of diabetes
EA022186B1 (ru)	2009-07-10	2015-11-30	Янссен Фармацевтика Нв	СПОСОБ КРИСТАЛЛИЗАЦИИ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-4-МЕТИЛ-3-[5-(4-ФТОРФЕНИЛ)-2-ТИЕНИЛМЕТИЛ]БЕНЗОЛА
JP5722901B2 (ja)	2009-09-15	2015-05-27	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎＰｈａｒｍａｃｅｕｔｉｃａＮａａｍｌｏｚｅＶｅｎｎｏｏｔｓｃｈａｐ	グルコースの吸収および排泄の指標としてのα−メチルグルコシド（ＡＭＧ）の使用
RS55909B1 (sr) *	2009-10-14	2017-09-29	Janssen Pharmaceutica Nv	Proces za pripremu jedinjenja koja su korisna kao inhibitori sglt2
US8394772B2 (en)	2009-10-20	2013-03-12	Novartis Ag	Glycoside derivative and uses thereof
SI2496583T1 (sl)	2009-11-02	2015-02-27	Pfizer Inc.	Derivati dioksa-biciklo(3.2.1)oktan-2,3,4-triola
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EA022365B1 (ru)	2010-05-11	2015-12-30	Янссен Фармацевтика Нв	Фармацевтические композиции, содержащие производные 1-(бета-d-глюкопиранозил)-2-тиенилметилбензола как ингибиторы нзпг
US8933024B2 (en)	2010-06-18	2015-01-13	Sanofi	Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
ES2612492T3 (es) *	2010-12-28	2017-05-17	Sanofi	Nuevos derivados de piridiminas, su preparación y su utilización farmacéutica como inhibidores de fosforilación de AKT (PKB)
FR2969614A1 (fr) *	2010-12-28	2012-06-29	Sanofi Aventis	Nouveaux derives de pyrimidinones, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
ES2586846T3 (es)	2011-04-13	2016-10-19	Janssen Pharmaceutica, N.V.	Proceso de preparación de compuestos útiles como inhibidores de SGLT2
US9035044B2 (en)	2011-05-09	2015-05-19	Janssen Pharmaceutica Nv	L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
US9522931B2 (en) *	2011-05-20	2016-12-20	Janssen Pharmaceutica Nv	Process for the preparation of compounds useful as inhibitors of SGLT-2
ES2626038T3 (es) *	2011-05-20	2017-07-21	Janssen Pharmaceutica, N.V.	Procesos para la preparación de compuestos útiles como inhibidores de sglt-2
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en)	2011-09-27	2013-04-04	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
TW201335176A (zh) *	2011-12-15	2013-09-01	Nat Health Research Institutes	新穎醣苷化合物
AR097890A1 (es)	2013-10-17	2016-04-20	Lilly Co Eli	Compuestos de urea
JO3298B1 (ar) *	2013-11-01	2018-09-16	Lilly Co Eli	مشتقات جليكوبيرانوسيل-مستبدل و اندول-يوريا و استعمالاتهم كمثبطات sglt
US20170071970A1 (en)	2015-09-15	2017-03-16	Janssen Pharmaceutica Nv	Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
JP7137318B2 (ja) *	2018-02-22	2022-09-14	オルガノ株式会社	被処理液の精製方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2102591C (en) *	1992-11-12	2000-12-26	Kenji Tsujihara	Hypoglycemic agent
US5731292A (en) *	1992-11-12	1998-03-24	Tanabe Seiyaku Co., Ltd.	Dihydrochalcone derivatives which are hypoglycemic agents
US5830873A (en) *	1994-05-11	1998-11-03	Tanabe Seiyaku Co., Ltd.	Propiophenone derivative and a process for preparing the same
US6515117B2 (en) *	1999-10-12	2003-02-04	Bristol-Myers Squibb Company	C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) *	1999-10-12	2006-02-21	Bristol Myers Squibb Co	C-aryl glucoside SGLT2 inhibitors
US6627611B2 (en) *	2000-02-02	2003-09-30	Kotobuki Pharmaceutical Co Ltd	C-glycosides and preparation of thereof as antidiabetic agents
JP4456768B2 (ja)	2000-02-02	2010-04-28	壽製薬株式会社	Ｃ−配糖体を含有する薬剤
ATE312114T1 (de)	2000-03-17	2005-12-15	Kissei Pharmaceutical	Glucopyranosyloxy-benzylbenzen-derivate, medizinische zusammensetzung und zwischenprodukte für die herstellung der derivate
US6683056B2 (en)	2000-03-30	2004-01-27	Bristol-Myers Squibb Company	O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en)	2000-03-30	2003-04-29	Bristol-Myers Squibb Company	O-glucosylated benzamide SGLT2 inhibitors and method
EP1354888B1 (en) *	2000-12-28	2009-05-20	Kissei Pharmaceutical Co., Ltd.	Glucopyranosyloxypyrazole derivatives and use thereof in medicines
DE60230591D1 (de) *	2001-02-26	2009-02-12	Kissei Pharmaceutical	Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
WO2002068440A1 (fr)	2001-02-27	2002-09-06	Kissei Pharmaceutical Co., Ltd.	Derives de glycopyranosyloxypyrazole et utilisation medicinale de ceux-ci
US6936590B2 (en) *	2001-03-13	2005-08-30	Bristol Myers Squibb Company	C-aryl glucoside SGLT2 inhibitors and method
DK1385856T3 (da)	2001-04-11	2006-05-15	Bristol Myers Squibb Co	Aminosyrekomplekser af C-aryl-glucosider til behandling af diabetes og fremgangsmåder
EP1389621A4 (en)	2001-04-27	2005-05-11	Ajinomoto Kk	N-SUBSTITUTED PYRAZOLYL-O-GLYCOSIDE DERIVATIVES AND DIABETES CONTAINING THEREOF
JP4115105B2 (ja)	2001-07-02	2008-07-09	協和醗酵工業株式会社	ピラゾール誘導体
WO2003011880A1 (fr)	2001-07-31	2003-02-13	Kissei Pharmaceutical Co., Ltd.	Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition
WO2003020737A1 (en)	2001-09-05	2003-03-13	Bristol-Myers Squibb Company	O-pyrazole glucoside sglt2 inhibitors and method of use
US6562791B1 (en) *	2002-03-29	2003-05-13	Council Of Scientific And Industrial Research	Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof
DE10231370B4 (de) *	2002-07-11	2006-04-06	Sanofi-Aventis Deutschland Gmbh	Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
TWI254635B (en)	2002-08-05	2006-05-11	Yamanouchi Pharma Co Ltd	Azulene derivative and salt thereof
PL372865A1 (en)	2002-08-09	2005-08-08	Taisho Pharmaceutical Co, Ltd.	Aryl 5-thio-beta-d-glucopyranoside derivatives and remedies for diabetes containing the same
AU2003262262A1 (en)	2002-08-27	2004-03-19	Kissei Pharmaceutical Co., Ltd.	Pyrazole derivatives, medicinal composition containing the same, and medicinal use thereof
DE10258008B4 (de)	2002-12-12	2006-02-02	Sanofi-Aventis Deutschland Gmbh	Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258007B4 (de) *	2002-12-12	2006-02-09	Sanofi-Aventis Deutschland Gmbh	Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
JP4222450B2 (ja)	2003-03-14	2009-02-12	アステラス製薬株式会社	Ｃ−グリコシド誘導体又はその塩
EP1680414A4 (en) *	2003-08-01	2009-05-27	Janssen Pharmaceutica Nv	SUBSTITUTED INDAZOLE-O-GLUCOSIDE
UA86042C2 (en) *	2003-08-01	2009-03-25	Янссен Фармацевтика Н.В.	Substituted indazole-o-glucosides
CA2534024C (en)	2003-08-01	2009-06-02	Tanabe Seiyaku Co., Ltd.	Novel compounds having inhibitory activity against sodium-dependant transporter
WO2005012243A2 (en) *	2003-08-01	2005-02-10	Janssen Pharmaceutica N.V.	Substituted indole-o-glucosides
AR048377A1 (es) *	2003-08-01	2006-04-26	Janssen Pharmaceutica Nv	Benzoimidazol-, benzotriazol- y benzoimidazolona - o- glucosidos sustituidos
WO2005012318A2 (en) *	2003-08-01	2005-02-10	Janssen Pharmaceutica Nv	Substituted fused heterocyclic c-glycosides
WO2006035796A1 (ja)	2004-09-29	2006-04-06	Kissei Pharmaceutical Co., Ltd.	１－（β－Ｄ－グリコピラノシル）－３－置換含窒素ヘテロ環化合物、それを含有する医薬組成物及びその医薬用途
AR053329A1 (es) *	2005-01-31	2007-05-02	Tanabe Seiyaku Co	Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
JP2008050353A (ja) *	2006-07-27	2008-03-06	Mitsubishi Tanabe Pharma Corp	医薬組成物

2007
- 2007-07-11 TW TW096125166A patent/TWI418556B/zh not_active IP Right Cessation
- 2007-07-25 UY UY30506A patent/UY30506A1/es unknown
- 2007-07-25 JO JO2007306A patent/JO2681B1/en active
- 2007-07-26 CL CL200702197A patent/CL2007002197A1/es unknown
- 2007-07-26 PE PE2007000981A patent/PE20080522A1/es not_active Application Discontinuation
- 2007-07-26 AR ARP070103316A patent/AR062111A1/es unknown
- 2007-07-26 US US11/878,760 patent/US7851617B2/en not_active Expired - Fee Related
- 2007-07-27 EP EP07791887A patent/EP2049557B1/en active Active
- 2007-07-27 DK DK07791887.8T patent/DK2049557T3/da active
- 2007-07-27 DE DE602007013056T patent/DE602007013056D1/de active Active
- 2007-07-27 JP JP2009521499A patent/JP5102294B2/ja not_active Expired - Fee Related
- 2007-07-27 AT AT07791887T patent/ATE501159T1/de active
- 2007-07-27 PT PT07791887T patent/PT2049557E/pt unknown
- 2007-07-27 EA EA200970161A patent/EA016819B1/ru not_active IP Right Cessation
- 2007-07-27 NZ NZ574072A patent/NZ574072A/en not_active IP Right Cessation
- 2007-07-27 AU AU2007277662A patent/AU2007277662B2/en not_active Ceased
- 2007-07-27 BR BRPI0715369-4A patent/BRPI0715369A2/pt not_active IP Right Cessation
- 2007-07-27 KR KR1020097004110A patent/KR101179312B1/ko not_active IP Right Cessation
- 2007-07-27 CA CA2658116A patent/CA2658116C/en not_active Expired - Fee Related
- 2007-07-27 MY MYPI20090277A patent/MY145106A/en unknown
- 2007-07-27 PL PL07791887T patent/PL2049557T3/pl unknown
- 2007-07-27 UA UAA200901760A patent/UA92100C2/uk unknown
- 2007-07-27 CN CN2007800277313A patent/CN101501053B/zh not_active Expired - Fee Related
- 2007-07-27 MX MX2009000995A patent/MX2009000995A/es active IP Right Grant
- 2007-07-27 WO PCT/JP2007/065213 patent/WO2008013322A1/en active Application Filing
2008
- 2008-12-19 NO NO20085337A patent/NO20085337L/no not_active Application Discontinuation
- 2008-12-30 IL IL196267A patent/IL196267A0/en not_active IP Right Cessation
2009
- 2009-01-22 GT GT200900014A patent/GT200900014A/es unknown
- 2009-01-26 HN HN2009000161A patent/HN2009000161A/es unknown
- 2009-01-26 CR CR10583A patent/CR10583A/es unknown
- 2009-01-27 CO CO09006937A patent/CO6150170A2/es unknown

Also Published As

Publication number	Publication date
EP2049557B1 (en)	2011-03-09
ATE501159T1 (de)	2011-03-15
UY30506A1 (es)	2008-01-31
KR101179312B1 (ko)	2012-09-03
BRPI0715369A2 (pt)	2013-06-18
EA016819B1 (ru)	2012-07-30
PT2049557E (pt)	2011-05-05
GT200900014A (es)	2010-02-09
JP5102294B2 (ja)	2012-12-19
AU2007277662B2 (en)	2011-02-03
CA2658116C (en)	2011-07-19
TW200811149A (en)	2008-03-01
CA2658116A1 (en)	2008-01-31
CN101501053A (zh)	2009-08-05
DE602007013056D1 (de)	2011-04-21
TWI418556B (zh)	2013-12-11
CN101501053B (zh)	2012-10-03
MX2009000995A (es)	2009-02-04
NZ574072A (en)	2011-05-27
CR10583A (es)	2009-06-05
JP2009544693A (ja)	2009-12-17
US20080027122A1 (en)	2008-01-31
AU2007277662A1 (en)	2008-01-31
KR20090040356A (ko)	2009-04-23
EA200970161A1 (ru)	2009-06-30
AR062111A1 (es)	2008-10-15
MY145106A (en)	2011-12-30
PL2049557T3 (pl)	2011-07-29
CO6150170A2 (es)	2010-04-20
EP2049557A1 (en)	2009-04-22
HN2009000161A (es)	2011-05-25
PE20080522A1 (es)	2008-06-13
UA92100C2 (uk)	2010-09-27
IL196267A0 (en)	2009-09-22
JO2681B1 (en)	2013-03-03
US7851617B2 (en)	2010-12-14
WO2008013322A1 (en)	2008-01-31
NO20085337L (no)	2009-04-24
CL2007002197A1 (es)	2008-02-15

Publication	Publication Date	Title
DK2049557T3 (da)	2011-06-14	1-(-D-glycopyranosyl)-3-(4-cyclopropylphenylmethyl)-4-halogenindolderivater og anvendelse heraf som sglt-inhibitorer
DK2099447T3 (da)	2013-02-18	Imidazotriaziner og imidazopyrimidiner som kinaseinhibitorer
DK2094263T3 (da)	2013-12-02	2-adamantyl-butyramidderivater som selektive 11 beta-hsd1-inhibitorer
DK1789041T3 (da)	2008-09-08	Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
DK2121614T3 (da)	2012-09-17	Aminonikotin og isonikotinsyrederivater som dhodh-inhibitorer
DK2086939T3 (da)	2010-10-11	Pyridiacarboxamid som II-beta-HSDI-inhibitorer
NO20084764L (no)	2009-01-06	Tioksantinderivater og deres anvendelse som MPO inhibitorer
NO20091423L (no)	2009-06-10	Pyrimidinderivater og deres anvendelse som kinaseinhibitorer
NO20084533L (no)	2009-01-09	Pyrimidin-derivat som PI3K-inhibitor og bruk av dette
DK1586319T3 (da)	2010-02-08	Thiadiazolidinoner som GSK-3-inhibitorer
DK2078001T3 (da)	2010-07-19	Diazepan-acetamidderivater som selektive 11-HSD1-inhibitorer
DK1797042T3 (da)	2009-03-02	Indozolonderivater som 11B-HSD1-inhibitorer
DK1960352T3 (da)	2013-10-28	2-adamantylurinstof-derivater som selektive 11beta-hsd1 inhibitorer
DK2041138T3 (da)	2014-08-11	Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da)	2011-06-27	Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
DK2066324T3 (da)	2013-08-26	Cycloalkanpyrrolocarbazolderivater og anvendelse deraf som parp, vegfr2 og mlk3 inhibitorer
DK2439205T3 (da)	2015-06-22	Carboxamidforbindelser og deres anvendelse som calpaininhibitorer
DK1940839T3 (da)	2013-10-14	Pyridopyrimidione Inhibitors of P13Ka
DK2383271T3 (da)	2013-10-07	Aminoquinoloner som GSK-3-inhibitorer
PT1586571E (pt)	2008-09-08	Inibidores da dipeptidil-peptidase
DK1989206T3 (da)	2012-10-08	E1-aktiveringsenzymhæmmere
CY2014012I1 (el)	2015-12-09	Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
DK1926722T3 (da)	2011-12-19	Substituerede benzimidazoler som kinaseinhibitorer
DK2074122T5 (da)	2014-03-17	Pyrido (2, 3-d) pyrimidin0n-forbindelser og anvendelse deraf som pi3 inhibitorer
DK1959951T3 (da)	2010-03-01	Heteroaryl-substituerede piperidinderivater som L-CPT1-inhibitorer